Table 3.

Patients’ Characteristics.

	All (115)	PHY (33)	UNI (82)	p value
Median age (median, range)	70 (38-91)	67 (47 -91)	71.5 (38-88)	0.12
<70 y.o./≥70 y.o.	56/59	20/13	36/46	0.11
Sex (M/F)	56/59	21/12	35/47	0.04
Stage (I,II/ III,IV)	34/81	8/25	26/56	0.43
PS 0-1/2-4/NA	73/31/11	17/10/6	56/21/5	0.33
Extranodal lesions 0-1/>2/NA	71/43/1	26/6/1	45/37/0	0.01
LDH (IU/L, median, range)	289 (134-3,033)	287 (134-1,267)	291 (144-3,033)	0.94
R-IPI (very good/good/poor/NA)	5/41/68/1	2/10/20/1	3/31/48/0	0.71
Albumin (g/dL, median, range)	3.4 (1.5-4.8)	3.5 (1.6-4.8)	3.3 (1.5-4.7)	0.048
Creatinine (mg/dL, median, range)	0.73 (0.31-13.22)	0.73 (0.4-3.27)	0.72 (0.31-13.22)	0.29
T.Bil (mg/dL, median, range)	0.7 (0.2-9.5)	0.6 (0.3-6.2)	0.7 (0.2-9.5)	0.034
AST (IU/L, median, range)	25 (9-728)	31 (9-665)	24 (12-728)	0.27
ALT (IU/L, median, range)	17 (5-795)	15 (5-795)	17 (6-554)	0.64
CCI (median, range)	2 (0-7)	2 (0-9)	3 (0-9)	0.74
CCI 0-2/≥3	60/55	15/18	45/37	0.41

ALT: alanine aminotransferase, AST: aspartate aminotransferase, CCI: Charlson Comorbidity Index, R-IPI: Revised International Prognostic Index, LDH: lactate dehydrogenase, NA: not available, PHY: physicians’ decision group, PS: performance status, T.Bil: total bilirubin, UNI: unified dose-attenuation group